<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502862</url>
  </required_header>
  <id_info>
    <org_study_id>LPS16677</org_study_id>
    <secondary_id>2020-001217-20</secondary_id>
    <secondary_id>U1111-1249-6054</secondary_id>
    <nct_id>NCT04502862</nct_id>
  </id_info>
  <brief_title>Dupilumab Asthma Sleep Study</brief_title>
  <acronym>MORPHEO</acronym>
  <official_title>A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the effect of dupilumab on sleep&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on additional patient reported sleep outcomes&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on objective sleep assessment&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on asthma symptoms&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on lung function&#xD;
&#xD;
        -  To evaluate the safety of dupilumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant will be approximately 16 weeks and up to 29 weeks including up&#xD;
      to 5 weeks screening period, a 12-week treatment period and up to 12 weeks post-treatment&#xD;
      follow-up period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Anticipated">September 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interim analysis for sample size re-estimation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sleep disturbance score in Asthma Sleep Disturbance Questionnaire</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in sleep disturbance score using the Asthma Sleep Disturbance Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the number of nocturnal awakenings in Sleep Diary</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in the number of nocturnal awakenings as recorded in Sleep Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS sleep-related impairment assessment</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment 8a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality in Sleep Diary</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in sleep quality (Sleep Diary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in restorative sleep in Sleep Diary</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in restorative sleep (Sleep Diary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WASO in Sleep Diary</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in wake after sleep onset (WASO) (Sleep Diary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WASO (actigraphy data)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in WASO based on actigraphy data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daytime and nighttime asthma symptoms in Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre-bronchodilator (BD) FEV1</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline to Week 12 in prebronchodilator forced expiratory volume in 1 second (pre-BD FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESI), including clinically significant changes in vital signs considered to be adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x dupilumab injections as loading dose on Day 1, followed by 1 dupilumab maintenance dose injection every 2 weeks (Q2W) during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x placebo injections on Day 1, then 1 placebo injection Q2W during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR231893</intervention_name>
    <description>Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <other_name>Dupixent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Physician diagnosis of asthma based on the Global Initiative for Asthma (GINA) 2020&#xD;
             Guidelines for ≥12 months treated with medium to high dose inhaled corticosteroid&#xD;
             (ICS) and a second controller (ie, long-acting beta agonist, leukotriene receptor&#xD;
             antagonist). A third controller is allowed but not mandatory. The dose regimen should&#xD;
             be stable for at least 1 month before the study and during the screening period&#xD;
&#xD;
          -  History of at least one asthma exacerbation within 1 year prior to screening.&#xD;
             Exacerbation is defined as deterioration of asthma that results in emergency&#xD;
             treatment, hospitalization due to asthma, or treatment with systemic steroids (oral or&#xD;
             injectable)&#xD;
&#xD;
          -  Eosinophils ≥150 cells/μL and fractional exhaled nitric oxide (FeNO) ≥25 ppb during&#xD;
             screening, prior to randomization&#xD;
&#xD;
               -  NOTES:&#xD;
&#xD;
               -  Historical values of blood eosinophil count meeting the eligibility criterion&#xD;
                  measured within 6 months prior to screening Visit 1 in the absence of oral&#xD;
                  corticosteroid (OCS) treatment are allowed&#xD;
&#xD;
               -  FeNO value to be checked for eligibility at Visit 2 as well&#xD;
&#xD;
          -  Asthma control questionnaire (ACQ)-5 ≥2.5 at screening Visit 1 and Visit 2, prior to&#xD;
             randomization&#xD;
&#xD;
          -  Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) ≤ 80% of predicted&#xD;
             normal during screening, prior to randomization&#xD;
&#xD;
          -  Exhibit bronchodilator reversibility (≥12% and 200 mL improvement in FEV1 post&#xD;
             short-acting beta agonist administration) during screening period, prior to&#xD;
             randomization, unless reversibility test meeting the inclusion criteria was done&#xD;
             within 6 months prior to screening Visit 1&#xD;
&#xD;
          -  Weekly average nocturnal awakenings due to asthma symptoms in the week prior to&#xD;
             screening Visit 1 is ≥1&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Former smoker for 10 years with a smoking history of &gt;10 pack-years&#xD;
&#xD;
          -  Asthma exacerbation during screening, prior to randomization&#xD;
&#xD;
          -  History or clinical evidence of chronic obstructive pulmonary disease (COPD) including&#xD;
             Asthma-COPD Overlap Syndrome (ACOS) or any other significant lung disease (eg, lung&#xD;
             fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension,&#xD;
             bronchiectasis, Churg-Strauss Syndrome)&#xD;
&#xD;
          -  History of or current evidence of clinically significant non-respiratory diseases that&#xD;
             in the opinion of the investigator may interfere with the aims of the study or put the&#xD;
             participant at undue risk&#xD;
&#xD;
          -  Active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of&#xD;
             incompletely treated TB will be excluded unless it is well documented by a specialist&#xD;
             that the participant has been adequately treated and can now start treatment with a&#xD;
             biologic agent, in the medical judgment of the Investigator and/or infectious disease&#xD;
             specialist. Tuberculosis testing would be performed on a country by country basis,&#xD;
             according to local guidelines if required by Regulatory Authorities or ethics boards&#xD;
&#xD;
          -  Diagnosed active endoparasitic infection; suspected or high risk of endoparasitic&#xD;
             infection, unless clinical and (if necessary) laboratory assessment have ruled out&#xD;
             active infection before randomization&#xD;
&#xD;
          -  History of human immunodeficiency (HIV) infection or positive HIV test at screening&#xD;
             Visit 1&#xD;
&#xD;
          -  Active chronic or acute infection requiring treatment with systemic antibiotics,&#xD;
             antivirals, antiprotozoals, or antifungals within 2 weeks before screening&#xD;
&#xD;
          -  Known or suspected immunodeficiency including history of invasive opportunistic&#xD;
             infections, despite infection resolution&#xD;
&#xD;
          -  Current evidence of clinically significant oncological disease&#xD;
&#xD;
          -  History of systemic hypersensitivity or anaphylaxis to any biologic therapy&#xD;
&#xD;
          -  Severe uncontrolled depression&#xD;
&#xD;
          -  Sleep disturbances not related to asthma, including sleep apnea, hypersomnia, or&#xD;
             insomnia secondary to chronic pain, atopic dermatitis (AD), COPD or other conditions&#xD;
&#xD;
          -  Participant who works night shift (ie, any work between 8 pm and 6 am)&#xD;
&#xD;
          -  Erratic sleep habits, as determined by the Investigator&#xD;
&#xD;
          -  Restless leg syndrome or periodic limb movement disorder&#xD;
&#xD;
          -  Chronic treatment with oral corticosteroid (OCS) for more than 2 weeks before&#xD;
             screening Visit 1&#xD;
&#xD;
          -  Participant taking sedative, anxiolytic, or hypnotic treatments, including melatonin,&#xD;
             within 3 months before randomization&#xD;
&#xD;
          -  Participant taking systemic sedative antihistamines (excluding newer generations of&#xD;
             antihistamines) or theophylline&#xD;
&#xD;
          -  Current treatment with antidepressants, lipophilic beta blockers, clonidine, opioids,&#xD;
             or other medications known to interfere with sleep and may confound the study&#xD;
             assessments, as determined by the Investigator&#xD;
&#xD;
          -  Participant who has taken biologic therapy (including dupilumab)/systemic&#xD;
             immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid&#xD;
             arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus&#xD;
             erythematosus, multiple sclerosis, etc) within 2 months or 5 half-lives before&#xD;
             screening Visit 1, whichever is longer&#xD;
&#xD;
          -  Treatment with live (attenuated) vaccine within 4 weeks before screening Visit 1&#xD;
&#xD;
               -  NOTE: For participants who have vaccination with live, attenuated vaccines&#xD;
                  planned during the course of the study (based on national vaccination&#xD;
                  schedule/local guidelines), it will be determined, after consultation with a&#xD;
                  physician, whether the administration of vaccine can be postponed until after the&#xD;
                  end of the study, (i.e. after the 12 week follow-up period off-treatment or until&#xD;
                  the participant switches to commercialized dupilumab or other biologic product,&#xD;
                  whichever comes first), or preponed to before the start of the study without&#xD;
                  compromising the health of the participant:&#xD;
&#xD;
               -  Participant for whom administration of live (attenuated) vaccine can be safely&#xD;
                  postponed would be eligible to enroll into the study&#xD;
&#xD;
               -  Participant who have their vaccination preponed can enroll in the study only&#xD;
                  after a gap of 4 weeks following administration of the vaccine&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400009</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400011</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400012</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400008</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420-4211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760002</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760005</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760003</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760004</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760006</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280005</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280002</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200001</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200007</name>
      <address>
        <city>Guimarães</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200003</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430001</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430006</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430005</name>
      <address>
        <city>Moscow</city>
        <zip>117546</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430007</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193231</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430004</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Lugo / Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240005</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040006</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040002</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040003</name>
      <address>
        <city>Kharkiv</city>
        <zip>61166</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040008</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040007</name>
      <address>
        <city>Kyiv</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040005</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

